Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

104.38 -2.79 (-2.60%)

Streaming Delayed Price Updated: 11:57 AM EDT, Aug 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	143,218
Open	106.01
Bid (Size)	104.31 (100)
Ask (Size)	104.61 (300)
Prev. Close	107.17
Today's Range	104.33 - 108.84
52wk Range	74.50 - 122.20
Shares Outstanding	66,684,077
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗

August 26, 2026

Duquesne Family Office has beefed up its healthcare holdings.

Via The Motley Fool

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

August 24, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	-0.6%	-0.6%
1 Month	+5.2%	+5.2%
3 Month	+18.8%	+18.8%
6 Month	+9.9%	+9.9%
1 Year	+0.2%	+0.2%

More News

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗

August 23, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

August 17, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts ↗

August 17, 2026

Via MarketBeat

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or

August 11, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

August 04, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗

August 04, 2026

Via Benzinga

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 04, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

August 04, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

July 08, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

June 15, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

June 13, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

June 12, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 29, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 28, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 26, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

May 12, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

My Top 3 Stocks to Buy in May ↗

May 07, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗

May 06, 2026

Via Benzinga

Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

May 06, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?

Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market

What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?

The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 104.38

When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 08/31/26 11:57 AM ET

What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.96B

How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?

Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.